JPS6156220B2 - - Google Patents

Info

Publication number: JPS6156220B2
Authority: JP; Japan
Prior art keywords: ahlg; human; lymphocytes; cells; globulin
Prior art date: 1977-05-11
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.): Expired

Application number

JP5390177A

Other languages

English (en)

Japanese (ja)

Other versions

JPS53139720A (en

Inventor

Takeshi Matsumoto

Masahiro Watanabe

Shinichi Morisue

Tadakazu Suyama

Atsushi Kondo

Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)

GC Biopharma Corp

Original Assignee

Green Cross Corp Korea

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1977-05-11

Filing date

1977-05-11

Publication date

1986-12-01

1977-05-11 Application filed by Green Cross Corp Korea filed Critical Green Cross Corp Korea

1977-05-11 Priority to JP5390177A priority Critical patent/JPS53139720A/ja

1978-12-06 Publication of JPS53139720A publication Critical patent/JPS53139720A/ja

1986-12-01 Publication of JPS6156220B2 publication Critical patent/JPS6156220B2/ja

Status Granted legal-status Critical Current

Links

210000004698 lymphocyte Anatomy 0.000 claims description 43
238000000034 method Methods 0.000 claims description 36
210000004027 cell Anatomy 0.000 claims description 31
108010044091 Globulins Proteins 0.000 claims description 11
102000006395 Globulins Human genes 0.000 claims description 11
230000002163 immunogen Effects 0.000 claims description 11
238000004519 manufacturing process Methods 0.000 claims description 11
241001465754 Metazoa Species 0.000 claims description 10
108010074605 gamma-Globulins Proteins 0.000 claims description 9
239000003814 drug Substances 0.000 claims description 4
229940079593 drug Drugs 0.000 claims description 3
102000004169 proteins and genes Human genes 0.000 claims description 3
108090000623 proteins and genes Proteins 0.000 claims description 3
238000011084 recovery Methods 0.000 claims 1
238000012360 testing method Methods 0.000 description 16
230000000694 effects Effects 0.000 description 13
210000003743 erythrocyte Anatomy 0.000 description 11
239000002244 precipitate Substances 0.000 description 9
238000010790 dilution Methods 0.000 description 7
239000012895 dilution Substances 0.000 description 7
210000002381 plasma Anatomy 0.000 description 7
241000282412 Homo Species 0.000 description 6
210000004369 blood Anatomy 0.000 description 6
239000008280 blood Substances 0.000 description 6
238000002474 experimental method Methods 0.000 description 6
230000003053 immunization Effects 0.000 description 6
238000002649 immunization Methods 0.000 description 6
239000000725 suspension Substances 0.000 description 6
230000002776 aggregation Effects 0.000 description 5
238000004220 aggregation Methods 0.000 description 5
230000000052 comparative effect Effects 0.000 description 5
210000005104 human peripheral blood lymphocyte Anatomy 0.000 description 5
230000007794 irritation Effects 0.000 description 5
239000002504 physiological saline solution Substances 0.000 description 5
210000002966 serum Anatomy 0.000 description 5
239000006228 supernatant Substances 0.000 description 5
241000283973 Oryctolagus cuniculus Species 0.000 description 4
FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 4
239000003146 anticoagulant agent Substances 0.000 description 4
230000015572 biosynthetic process Effects 0.000 description 4
238000005119 centrifugation Methods 0.000 description 4
239000012528 membrane Substances 0.000 description 4
210000003205 muscle Anatomy 0.000 description 4
210000004623 platelet-rich plasma Anatomy 0.000 description 4
208000010110 spontaneous platelet aggregation Diseases 0.000 description 4
238000011282 treatment Methods 0.000 description 4
101710154606 Hemagglutinin Proteins 0.000 description 3
101710093908 Outer capsid protein VP4 Proteins 0.000 description 3
101710135467 Outer capsid protein sigma-1 Proteins 0.000 description 3
101710176177 Protein A56 Proteins 0.000 description 3
231100000215 acute (single dose) toxicity testing Toxicity 0.000 description 3
238000011047 acute toxicity test Methods 0.000 description 3
BFNBIHQBYMNNAN-UHFFFAOYSA-N ammonium sulfate Chemical compound N.N.OS(O)(=O)=O BFNBIHQBYMNNAN-UHFFFAOYSA-N 0.000 description 3
229910052921 ammonium sulfate Inorganic materials 0.000 description 3
235000011130 ammonium sulphate Nutrition 0.000 description 3
230000000781 anti-lymphocytic effect Effects 0.000 description 3
230000000702 anti-platelet effect Effects 0.000 description 3
210000001772 blood platelet Anatomy 0.000 description 3
239000006285 cell suspension Substances 0.000 description 3
231100000263 cytotoxicity test Toxicity 0.000 description 3
239000012153 distilled water Substances 0.000 description 3
239000000185 hemagglutinin Substances 0.000 description 3
229920000669 heparin Polymers 0.000 description 3
230000001506 immunosuppresive effect Effects 0.000 description 3
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 3
208000011691 Burkitt lymphomas Diseases 0.000 description 2
CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 2
LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 2
229920001917 Ficoll Polymers 0.000 description 2
239000012981 Hank's balanced salt solution Substances 0.000 description 2
HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 description 2
241001494479 Pecora Species 0.000 description 2
241000700605 Viruses Species 0.000 description 2
239000007982 barbital buffer Substances 0.000 description 2
210000000601 blood cell Anatomy 0.000 description 2
238000010241 blood sampling Methods 0.000 description 2
230000000295 complement effect Effects 0.000 description 2
238000001914 filtration Methods 0.000 description 2
239000011521 glass Substances 0.000 description 2
229960002897 heparin Drugs 0.000 description 2
238000010562 histological examination Methods 0.000 description 2
238000001727 in vivo Methods 0.000 description 2
238000002347 injection Methods 0.000 description 2
239000007924 injection Substances 0.000 description 2
210000002751 lymph Anatomy 0.000 description 2
239000000203 mixture Substances 0.000 description 2
238000002360 preparation method Methods 0.000 description 2
238000000746 purification Methods 0.000 description 2
230000001954 sterilising effect Effects 0.000 description 2
238000004659 sterilization and disinfection Methods 0.000 description 2
231100000419 toxicity Toxicity 0.000 description 2
230000001988 toxicity Effects 0.000 description 2
238000002054 transplantation Methods 0.000 description 2
238000011179 visual inspection Methods 0.000 description 2
BFSVOASYOCHEOV-UHFFFAOYSA-N 2-diethylaminoethanol Chemical compound CCN(CC)CCO BFSVOASYOCHEOV-UHFFFAOYSA-N 0.000 description 1
IYLLULUTZPKQBW-UHFFFAOYSA-N Acrinol Chemical compound CC(O)C(O)=O.C1=C(N)C=CC2=C(N)C3=CC(OCC)=CC=C3N=C21 IYLLULUTZPKQBW-UHFFFAOYSA-N 0.000 description 1
239000011547 Bouin solution Substances 0.000 description 1
108091003079 Bovine Serum Albumin Proteins 0.000 description 1
208000023611 Burkitt leukaemia Diseases 0.000 description 1
241000700199 Cavia porcellus Species 0.000 description 1
241000282693 Cercopithecidae Species 0.000 description 1
GUBGYTABKSRVRQ-WFVLMXAXSA-N DEAE-cellulose Chemical compound OC1C(O)C(O)C(CO)O[C@H]1O[C@@H]1C(CO)OC(O)C(O)C1O GUBGYTABKSRVRQ-WFVLMXAXSA-N 0.000 description 1
229920002307 Dextran Polymers 0.000 description 1
206010016654 Fibrosis Diseases 0.000 description 1
208000032843 Hemorrhage Diseases 0.000 description 1
102000014150 Interferons Human genes 0.000 description 1
108010050904 Interferons Proteins 0.000 description 1
206010028980 Neoplasm Diseases 0.000 description 1
206010030113 Oedema Diseases 0.000 description 1
241000282579 Pan Species 0.000 description 1
239000002202 Polyethylene glycol Substances 0.000 description 1
241000700159 Rattus Species 0.000 description 1
208000007536 Thrombosis Diseases 0.000 description 1
GLNADSQYFUSGOU-GPTZEZBUSA-J Trypan blue Chemical compound [Na+].[Na+].[Na+].[Na+].C1=C(S([O-])(=O)=O)C=C2C=C(S([O-])(=O)=O)C(/N=N/C3=CC=C(C=C3C)C=3C=C(C(=CC=3)\N=N\C=3C(=CC4=CC(=CC(N)=C4C=3O)S([O-])(=O)=O)S([O-])(=O)=O)C)=C(O)C2=C1N GLNADSQYFUSGOU-GPTZEZBUSA-J 0.000 description 1
102000004142 Trypsin Human genes 0.000 description 1
108090000631 Trypsin Proteins 0.000 description 1
MZVQCMJNVPIDEA-UHFFFAOYSA-N [CH2]CN(CC)CC Chemical group [CH2]CN(CC)CC MZVQCMJNVPIDEA-UHFFFAOYSA-N 0.000 description 1
230000004913 activation Effects 0.000 description 1
239000002671 adjuvant Substances 0.000 description 1
238000001042 affinity chromatography Methods 0.000 description 1
230000004520 agglutination Effects 0.000 description 1
239000003708 ampul Substances 0.000 description 1
150000001450 anions Chemical class 0.000 description 1
230000002391 anti-complement effect Effects 0.000 description 1
229940127219 anticoagulant drug Drugs 0.000 description 1
108010008730 anticomplement Proteins 0.000 description 1
239000000427 antigen Substances 0.000 description 1
230000000890 antigenic effect Effects 0.000 description 1
102000036639 antigens Human genes 0.000 description 1
108091007433 antigens Proteins 0.000 description 1
239000007864 aqueous solution Substances 0.000 description 1
201000011510 cancer Diseases 0.000 description 1
229910002092 carbon dioxide Inorganic materials 0.000 description 1
239000001569 carbon dioxide Substances 0.000 description 1
230000004663 cell proliferation Effects 0.000 description 1
230000001413 cellular effect Effects 0.000 description 1
230000008859 change Effects 0.000 description 1
150000001875 compounds Chemical class 0.000 description 1
239000006059 cover glass Substances 0.000 description 1
239000012531 culture fluid Substances 0.000 description 1
210000004748 cultured cell Anatomy 0.000 description 1
210000004544 dc2 Anatomy 0.000 description 1
230000034994 death Effects 0.000 description 1
231100000517 death Toxicity 0.000 description 1
230000007850 degeneration Effects 0.000 description 1
238000011161 development Methods 0.000 description 1
238000000502 dialysis Methods 0.000 description 1
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
208000035475 disorder Diseases 0.000 description 1
230000002500 effect on skin Effects 0.000 description 1
239000000839 emulsion Substances 0.000 description 1
238000011067 equilibration Methods 0.000 description 1
239000012091 fetal bovine serum Substances 0.000 description 1
230000004761 fibrosis Effects 0.000 description 1
239000000706 filtrate Substances 0.000 description 1
238000010438 heat treatment Methods 0.000 description 1
ZFGMDIBRIDKWMY-PASTXAENSA-N heparin Chemical compound CC(O)=N[C@@H]1[C@@H](O)[C@H](O)[C@@H](COS(O)(=O)=O)O[C@@H]1O[C@@H]1[C@@H](C(O)=O)O[C@@H](O[C@H]2[C@@H]([C@@H](OS(O)(=O)=O)[C@@H](O[C@@H]3[C@@H](OC(O)[C@H](OS(O)(=O)=O)[C@H]3O)C(O)=O)O[C@@H]2O)CS(O)(=O)=O)[C@H](O)[C@H]1O ZFGMDIBRIDKWMY-PASTXAENSA-N 0.000 description 1
229960001008 heparin sodium Drugs 0.000 description 1
208000006454 hepatitis Diseases 0.000 description 1
231100000283 hepatitis Toxicity 0.000 description 1
210000002865 immune cell Anatomy 0.000 description 1
230000036737 immune function Effects 0.000 description 1
230000028993 immune response Effects 0.000 description 1
229960003444 immunosuppressant agent Drugs 0.000 description 1
230000001861 immunosuppressant effect Effects 0.000 description 1
239000003018 immunosuppressive agent Substances 0.000 description 1
230000008595 infiltration Effects 0.000 description 1
238000001764 infiltration Methods 0.000 description 1
230000005764 inhibitory process Effects 0.000 description 1
229940079322 interferon Drugs 0.000 description 1
150000002500 ions Chemical class 0.000 description 1
210000000265 leukocyte Anatomy 0.000 description 1
231100000053 low toxicity Toxicity 0.000 description 1
238000005259 measurement Methods 0.000 description 1
238000002156 mixing Methods 0.000 description 1
230000017074 necrotic cell death Effects 0.000 description 1
231100000956 nontoxicity Toxicity 0.000 description 1
210000000056 organ Anatomy 0.000 description 1
230000001717 pathogenic effect Effects 0.000 description 1
230000000144 pharmacologic effect Effects 0.000 description 1
229940012957 plasmin Drugs 0.000 description 1
229920001223 polyethylene glycol Polymers 0.000 description 1
229920000151 polyglycol Polymers 0.000 description 1
239000010695 polyglycol Substances 0.000 description 1
230000008569 process Effects 0.000 description 1
230000035755 proliferation Effects 0.000 description 1
230000000717 retained effect Effects 0.000 description 1
239000012898 sample dilution Substances 0.000 description 1
239000013049 sediment Substances 0.000 description 1
238000004062 sedimentation Methods 0.000 description 1
238000013207 serial dilution Methods 0.000 description 1
239000011780 sodium chloride Substances 0.000 description 1
239000000243 solution Substances 0.000 description 1
238000010186 staining Methods 0.000 description 1
239000000126 substance Substances 0.000 description 1
239000013589 supplement Substances 0.000 description 1
230000001629 suppression Effects 0.000 description 1
230000004083 survival effect Effects 0.000 description 1
230000001225 therapeutic effect Effects 0.000 description 1
238000012546 transfer Methods 0.000 description 1
230000007704 transition Effects 0.000 description 1
239000012588 trypsin Substances 0.000 description 1
238000002525 ultrasonication Methods 0.000 description 1
230000003442 weekly effect Effects 0.000 description 1
238000005303 weighing Methods 0.000 description 1

Landscapes

Preparation Of Compounds By Using Micro-Organisms (AREA)
Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Peptides Or Proteins (AREA)

JP5390177A 1977-05-11 1977-05-11 Production of antihumanlymphociteglobulin (ahlg) Granted JPS53139720A (en)

Priority Applications (1)

Application Number	Priority Date	Filing Date	Title
JP5390177A JPS53139720A (en)	1977-05-11	1977-05-11	Production of antihumanlymphociteglobulin (ahlg)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
JP5390177A JPS53139720A (en)	1977-05-11	1977-05-11	Production of antihumanlymphociteglobulin (ahlg)

Publications (2)

Publication Number	Publication Date
JPS53139720A JPS53139720A (en)	1978-12-06
JPS6156220B2 true JPS6156220B2 (de)	1986-12-01

Family

ID=12955612

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
JP5390177A Granted JPS53139720A (en)	1977-05-11	1977-05-11	Production of antihumanlymphociteglobulin (ahlg)

Country Status (1)

Country	Link
JP (1)	JPS53139720A (de)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
IL69686A (en) *	1983-09-11	1988-03-31	Yeda Res & Dev	Compositions containing cell membrane proteins and process for their preparation

1977
- 1977-05-11 JP JP5390177A patent/JPS53139720A/ja active Granted

Also Published As

Publication number	Publication date
JPS53139720A (en)	1978-12-06

Publication	Publication Date	Title
Touraine et al.	1975	T-lymphocytes and serum inhibitors of cell-mediated immunity in renal insufficiency
Paulus et al.	1977	Lymphocyte involvement in rheumatoid arthritis
Llende et al.	1986	Immunobiological consequences of splenectomy: a review
Krantz	1972	Studies on red cell aplasia. III. Treatment with horse antihuman thymocyte gamma globulin
DE2658170A1 (de)	1977-07-07	Arzneimittel zur behandlung der durch den hepatitisvirus b ausgeloesten akuten oder chronischen infektionen
Delgado et al.	1981	Dialyzable leukocyte extract therapy in immunodepressed patients with cutaneous leishmaniasis
US4009257A (en)	1977-02-22	Preparation of immunosuppressive materials
US5885570A (en)	1999-03-23	Induction of tolerance with modified immunogens
Miller et al.	1967	Thymic dysplasia (“Swiss agammaglobulinemia”): II. Morphologic and functional observations
Basten et al.	1978	T cell‐dependent suppression of antibody production. I. Characteristics of suppressor T cells following tolerance induction
Parish et al.	1968	Peripheral Blood Eosinophilia in Guinea‐pigs Following Implantation of Anaphylactic Guinea‐pig and Human Lung
Nelken et al.	1961	Late clouding of experimental corneal grafts
JPS6156220B2 (de)	1986-12-01
MELENEY et al.	1917	POST-TRANSFUSION REACTIONS: A REVIEW OF 280 TRANSFUSIONS PERFORMED IN THE WARDS OF PRESBYTERIAN HOSPITAL, NEW YORK CITY.
JPS625131B2 (de)	1987-02-03
Jensen et al.	1972	Complement-mediated vasoconstriction and graft rejection
Chapel et al.	1973	Rosette inhibition test in severely burned patients
Errett et al.	1985	The effect of pretransplant platelet transfusions on renal allograft survival and sensitization in dogs 1
Konomi et al.	1968	Preparation and purification of horse antihuman lymphocyte globulin (ALG)
JPS59116224A (ja)	1984-07-05	免疫反応を抑制する組成物およびその製法
Ring et al.	1976	Improved compatibility of ALG therapy by application of aggregate free globulin
JPS6260106B2 (de)	1987-12-15
Jewell et al.	1975	Isolation of parietal cells from guinea-pig gastric mucosa and the immunological characterization of their antigenic structure.
Rose et al.	1973	Variations in complement levels during active and adoptive immunization
JP3106509B2 (ja)	2000-11-06	抗ヒトリンパ球抗体の製造方法